Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CGON Stock 12 Month Forecast
Average Price Target
$63.11
▲(89.29% Upside)
| Highest Price Target$82.00 | Average Price Target$63.11 | Lowest Price Target$50.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$55
Buy
64.97%
Upside
Reiterated
09/10/25
Bank of America Securities
$62
Buy
85.96%
Upside
Reiterated
09/10/25
LifeSci Capital
$82
Buy
145.95%
Upside
Reiterated
09/08/25
Promising Phase 3 Results for CG Oncology's Cretostimogene Highlight Competitive Edge in Bladder Cancer TreatmentOver the weekend, CG Oncology presented updated 24-month complete response (CR) data from the Phase 3 BOND-003 study invesgang cretosmogene (targeted oncolyc virus) for the treatment of BCG-unresponsive high risk (HR) non muscle invasive bladder cancer (NMIBC) - LINK to the presentaon.
H.C. Wainwright
$75
Buy
124.96%
Upside
Reiterated
09/08/25
Promising Outlook for CG Oncology, Inc.: Buy Rating Supported by Cretostimogene's Efficacy and Market PotentialValuation and risks to achievement of price target. Our 12-month price target of $75 is based on an equally weighted composite of (a) 86.65/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $12.01 discounted back to and (b) an NPV of $64.2/ share (discount rate 12.0%, growth rate 3.0%). The assumptions are in line with the expected P/ E multiple and discount rate of a late development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.
JonesTrading
$50
Buy
49.97%
Upside
Initiated
09/08/25
Buy Rating for CG Oncology: Promising NMIBC Treatment and Strong Financial PositionCG Oncology is a late-stage company developing an oncolytic virus, cretostimogene grenadenorepvec (creto), in multiple settings of Cancer (NMIBC). In recent years, the NMIBC space has seen several new drugs entering the clinic with varying modalities in response to a supply shortage of the BCG vaccine used as a standard of care.
Cantor Fitzgerald
$75
Buy
124.96%
Upside
Reiterated
09/07/25
Morgan Stanley
$56
Buy
67.97%
Upside
Reiterated
09/05/25
RBC Capital
$53
Buy
58.97%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/08/25
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.
Goldman Sachs
―
Buy
―
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Scotiabank
$23
Hold
-31.01%
Downside
Reiterated
05/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$55
Buy
64.97%
Upside
Reiterated
09/10/25
Bank of America Securities
$62
Buy
85.96%
Upside
Reiterated
09/10/25
LifeSci Capital
$82
Buy
145.95%
Upside
Reiterated
09/08/25
Promising Phase 3 Results for CG Oncology's Cretostimogene Highlight Competitive Edge in Bladder Cancer TreatmentOver the weekend, CG Oncology presented updated 24-month complete response (CR) data from the Phase 3 BOND-003 study invesgang cretosmogene (targeted oncolyc virus) for the treatment of BCG-unresponsive high risk (HR) non muscle invasive bladder cancer (NMIBC) - LINK to the presentaon.
H.C. Wainwright
$75
Buy
124.96%
Upside
Reiterated
09/08/25
Promising Outlook for CG Oncology, Inc.: Buy Rating Supported by Cretostimogene's Efficacy and Market PotentialValuation and risks to achievement of price target. Our 12-month price target of $75 is based on an equally weighted composite of (a) 86.65/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $12.01 discounted back to and (b) an NPV of $64.2/ share (discount rate 12.0%, growth rate 3.0%). The assumptions are in line with the expected P/ E multiple and discount rate of a late development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.
JonesTrading
$50
Buy
49.97%
Upside
Initiated
09/08/25
Buy Rating for CG Oncology: Promising NMIBC Treatment and Strong Financial PositionCG Oncology is a late-stage company developing an oncolytic virus, cretostimogene grenadenorepvec (creto), in multiple settings of Cancer (NMIBC). In recent years, the NMIBC space has seen several new drugs entering the clinic with varying modalities in response to a supply shortage of the BCG vaccine used as a standard of care.
Cantor Fitzgerald
$75
Buy
124.96%
Upside
Reiterated
09/07/25
Morgan Stanley
$56
Buy
67.97%
Upside
Reiterated
09/05/25
RBC Capital
$53
Buy
58.97%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/08/25
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.
Goldman Sachs
―
Buy
―
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Scotiabank
$23
Hold
-31.01%
Downside
Reiterated
05/14/25
Best Analysts Covering CG Oncology, Inc.
1 Month
xxx
Success Rate
4/5 ratings generated profit
Average Return
+8.36%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +8.36% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+13.82%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +13.82% per trade.
1 Year
Success Rate
5/5 ratings generated profit
Average Return
+29.88%
reiterated a buy rating 9 days ago
Copying Sean Laaman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +29.88% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+29.88%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CGON Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
18
14
11
12
14
Buy
4
4
5
4
5
Hold
11
13
14
15
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
31
30
31
33
Each month's total comprises the sum of three months' worth of ratings.
CGON Financial Forecast
CGON Stock Forecast FAQ
What is CGON’s average 12-month price target, according to analysts?
Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 63.11.
What is CGON’s upside potential, based on the analysts’ average price target?
CG Oncology, Inc. has 89.29% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CGON a Buy, Sell or Hold?
CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is CG Oncology, Inc.’s price target?
The average price target for CG Oncology, Inc. is 63.11. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $82.00 ,the lowest forecast is $50.00. The average price target represents 89.29% Increase from the current price of $33.34.
The highest analyst price target is $82.00 ,the lowest forecast is $50.00. The average price target represents 89.29% Increase from the current price of $33.34.
What do analysts say about CG Oncology, Inc.?
CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of CGON?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.